Skip to main content
The Markets by Proactive
Go to Proactive Australia

Archive

PAVmed subsidiary Lucid Diagnostics to target consumers directly with EsoGuard Telemedicine launch

PAVmed subsidiary Lucid Diagnostics to target consumers directly with EsoGuard Telemedicine launch

PAVmed CEO Dr Lishan Aklog talks to Proactive about recent progress its subsidiary Lucid Diagnostics has made. Aklog says today the cancer prevention medical diagnostics company, which recently went public on the Nasdaq, has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth. Aklog explains how this program aims to progress.